aTyr Pharma’s (ATYR) Market Perform Rating Reaffirmed at Leerink Partners

by · The Markets Daily

aTyr Pharma (NASDAQ:ATYR – Get Free Report)‘s stock had its “market perform” rating reiterated by Leerink Partners in a note issued to investors on Monday, Marketbeat Ratings reports.

Several other equities research analysts have also commented on ATYR. Jefferies Financial Group boosted their price target on aTyr Pharma from $9.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, August 22nd. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of aTyr Pharma in a research note on Wednesday, June 4th. Wells Fargo & Company upped their price objective on aTyr Pharma from $17.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, June 20th. Wall Street Zen downgraded aTyr Pharma from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Finally, Cantor Fitzgerald downgraded aTyr Pharma from an “overweight” rating to a “neutral” rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, aTyr Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $23.25.

Get Our Latest Stock Analysis on ATYR

aTyr Pharma Stock Performance

ATYR stock traded down $5.01 during trading on Monday, hitting $1.03. The company had a trading volume of 135,261,438 shares, compared to its average volume of 3,440,024. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $5.36 and a 200-day moving average price of $4.39. aTyr Pharma has a 1-year low of $1.00 and a 1-year high of $7.29. The firm has a market cap of $100.44 million, a PE ratio of -1.29 and a beta of 1.01.

aTyr Pharma (NASDAQ:ATYR – Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). On average, analysts expect that aTyr Pharma will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ATYR. California State Teachers Retirement System acquired a new position in aTyr Pharma in the second quarter worth approximately $28,000. Group One Trading LLC acquired a new position in aTyr Pharma in the fourth quarter worth approximately $26,000. XTX Topco Ltd grew its position in aTyr Pharma by 74.9% in the first quarter. XTX Topco Ltd now owns 19,556 shares of the company’s stock worth $59,000 after buying an additional 8,374 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new position in aTyr Pharma in the second quarter worth approximately $45,000. Finally, Main Street Financial Solutions LLC grew its position in aTyr Pharma by 7.0% in the second quarter. Main Street Financial Solutions LLC now owns 143,600 shares of the company’s stock worth $728,000 after buying an additional 9,350 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

aTyr Pharma Company Profile

(Get Free Report)

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

See Also